

# Priscilla K Brastianos

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/9322015/priscilla-k-brastianos-publications-by-citations.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

203  
papers

7,823  
citations

47  
h-index

84  
g-index

221  
ext. papers

10,954  
ext. citations

8.5  
avg, IF

6.02  
L-index

#	Paper	IF	Citations
203	Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. <i>Cancer Discovery</i> , <b>2015</b> , 5, 1164-1177	24.4	581
202	An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma. <i>Cell</i> , <b>2019</b> , 178, 835-849	46.21	556
201	Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq. <i>Science</i> , <b>2017</b> , 355,	33.3	455
200	Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. <i>Nature Genetics</i> , <b>2013</b> , 45, 285-9	36.3	397
199	Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. <i>Nature Genetics</i> , <b>2014</b> , 46, 161-5	36.3	320
198	Analysis of tumour- and stroma-supplied proteolytic networks reveals a brain-metastasis-promoting role for cathepsin S. <i>Nature Cell Biology</i> , <b>2014</b> , 16, 876-88	23.4	227
197	Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2013</b> , 110, 8188-93	11.5	156
196	Longitudinal molecular trajectories of diffuse glioma in adults. <i>Nature</i> , <b>2019</b> , 576, 112-120	50.4	151
195	Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma. <i>Neuro-Oncology</i> , <b>2016</b> , 18, 649-55	1	144
194	Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy. <i>Journal of the National Cancer Institute</i> , <b>2016</b> , 108,	9.7	144
193	Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib. <i>Journal of Thoracic Oncology</i> , <b>2015</b> , 10, 232-6	8.9	124
192	Tuberculosis-associated haemophagocytic syndrome. <i>Lancet Infectious Diseases</i> , <b>2006</b> , 6, 447-54	25.5	119
191	The Evolving Landscape of Brain Metastasis. <i>Trends in Cancer</i> , <b>2018</b> , 4, 176-196	12.5	110
190	Leptomeningeal metastasis from systemic cancer: Review and update on management. <i>Cancer</i> , <b>2018</b> , 124, 21-35	6.4	105
189	Infiltrating T Cells Increase IDO1 Expression in Glioblastoma and Contribute to Decreased Patient Survival. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 6650-6660	12.9	104
188	Alterations in Pericyte Subpopulations Are Associated with Elevated Blood-Tumor Barrier Permeability in Experimental Brain Metastasis of Breast Cancer. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 5287-5299	12.9	98
187	Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma. <i>Oncotarget</i> , <b>2015</b> , 6, 4704-16	3.3	92

186	Advances in meningioma genetics: novel therapeutic opportunities. <i>Nature Reviews Neurology</i> , <b>2018</b> , 14, 106-115	15	80
185	DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management. <i>Neuro-Oncology</i> , <b>2019</b> , 21, 901-910	1	79
184	Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma. <i>Nature Genetics</i> , <b>2020</b> , 52, 371-377	36.3	78
183	CMET-16. THE ROLE OF SURGICAL RESECTION OF MELANOMA BRAIN METASTASES IN THE IMMUNOTHERAPY ERA. <i>Neuro-Oncology</i> , <b>2017</b> , 19, vi42-vi42	1	78
182	BMET-04LEPTOMENINGEAL CARCINOMATOSIS IN MELANOMA. <i>Neuro-Oncology</i> , <b>2015</b> , 17, v45.4-v45	1	78
181	04. ASSESSMENT OF EFFICACY AND SAFETY OF OSIMERTINIB FOR PATIENTS WITH INTRACRANIAL METASTATIC DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS. <i>Neuro-Oncology Advances</i> , <b>2020</b> , 2, ii1-ii1	0.9	78
180	RARE-04. TARGETED TREATMENT OF PAPILLARY CRANIOPHARYNGIOMAS HARBORING BRAFV600E MUTATIONS. <i>Neuro-Oncology</i> , <b>2019</b> , 21, vi222-vi222	1	78
179	NIMG-43. LONGITUDINAL TRACKING AND GROWTH RATE CHARACTERIZATION OF BRAIN METASTASES ON MAGNETIC RESONANCE IMAGING. <i>Neuro-Oncology</i> , <b>2019</b> , 21, vi170-vi171	1	78
178	TMOD-24. DEVELOPMENT OF A NOVEL IN VIVO MODEL OF LUNG-TO-BRAIN METASTASIS PROGRESSION. <i>Neuro-Oncology</i> , <b>2019</b> , 21, vi267-vi268	1	78
177	GENE-63. GENOMIC CHARACTERIZATION OF HUMAN BRAIN METASTASES IDENTIFIES NOVEL DRIVERS OF LUNG ADENOCARCINOMA PROGRESSION. <i>Neuro-Oncology</i> , <b>2019</b> , 21, vi111-vi111	1	78
176	GENE-18. DIVERGENT CLONAL EVOLUTION OF MELANOMA BRAIN METASTASES DURING TREATMENT WITH IMMUNOTHERAPY. <i>Neuro-Oncology</i> , <b>2018</b> , 20, vi106-vi107	1	78
175	CMET-16. THE ROLE OF SURGICAL RESECTION OF MELANOMA BRAIN METASTASES IN THE IMMUNOTHERAPY ERA. <i>Neuro-Oncology</i> , <b>2018</b> , 20, vi56-vi57	1	78
174	Brain metastasis. <i>Nature Reviews Cancer</i> , <b>2020</b> , 20, 4-11	31.3	77
173	Clinical Activity of Alectinib in Advanced RET-Rearranged Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , <b>2016</b> , 11, 2027-2032	8.9	75
172	Melanoma central nervous system metastases: current approaches, challenges, and opportunities. <i>Pigment Cell and Melanoma Research</i> , <b>2016</b> , 29, 627-642	4.5	74
171	Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applications. <i>Neuro-Oncology</i> , <b>2019</b> , 21, 571-584	1	67
170	Pervasive chromosomal instability and karyotype order in tumour evolution. <i>Nature</i> , <b>2020</b> , 587, 126-132	50.4	67
169	Landscape of Genomic Alterations in Pituitary Adenomas. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 1841-1851	12.9	64

168	Reactive astrocytic S1P3 signaling modulates the blood-tumor barrier in brain metastases. <i>Nature Communications</i> , <b>2018</b> , 9, 2705	17.4	62
167	Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on the Role of Surgery in the Management of Adults With Metastatic Brain Tumors. <i>Neurosurgery</i> , <b>2019</b> , 84, E152-E155	3.2	62
166	Intratumoral heterogeneity and promoter mutations in progressive/higher-grade meningiomas. <i>Oncotarget</i> , <b>2017</b> , 8, 109228-109237	3.3	61
165	Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. <i>Neuro-Oncology</i> , <b>2017</b> , 19, 535-545	1	60
164	Prognostic and predictive value of epigenetic silencing of MGMT in patients with high grade gliomas: a systematic review and meta-analysis. <i>Journal of Neuro-Oncology</i> , <b>2011</b> , 105, 325-35	4.8	58
163	Radiation Treatment for WHO Grade II and III Meningiomas. <i>Frontiers in Oncology</i> , <b>2013</b> , 3, 227	5.3	56
162	Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis. <i>Cell</i> , <b>2021</b> , 184, 1281-1298.e26	56.2	55
161	Imaging and diagnostic advances for intracranial meningiomas. <i>Neuro-Oncology</i> , <b>2019</b> , 21, i44-i61	1	55
160	Rapid Intraoperative Molecular Characterization of Glioma. <i>JAMA Oncology</i> , <b>2015</b> , 1, 662-7	13.4	53
159	Concurrent therapy with immune checkpoint inhibitors and TNF blockade in patients with gastrointestinal immune-related adverse events <b>2019</b> , 7, 226		52
158	Updates in prognostic markers for gliomas. <i>Neuro-Oncology</i> , <b>2018</b> , 20, vii17-vii26	1	51
157	BRAF alteration status and the histone H3F3A gene K27M mutation segregate spinal cord astrocytoma histology. <i>Acta Neuropathologica</i> , <b>2016</b> , 131, 147-50	14.3	48
156	A Hematogenous Route for Medulloblastoma Leptomeningeal Metastases. <i>Cell</i> , <b>2018</b> , 172, 1050-1062.e14	14.2	46
155	Angiomatous meningiomas have a distinct genetic profile with multiple chromosomal polysomies including polysomy of chromosome 5. <i>Oncotarget</i> , <b>2014</b> , 5, 10596-606	3.3	46
154	Predictive molecular markers in metastases to the central nervous system: recent advances and future avenues. <i>Acta Neuropathologica</i> , <b>2014</b> , 128, 879-91	14.3	46
153	Molecular and translational advances in meningiomas. <i>Neuro-Oncology</i> , <b>2019</b> , 21, i4-i17	1	46
152	Consensus recommendations for a standardized brain tumor imaging protocol for clinical trials in brain metastases. <i>Neuro-Oncology</i> , <b>2020</b> , 22, 757-772	1	45
151	Alectinib Dose Escalation Reinduces Central Nervous System Responses in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer Relapsing on Standard Dose Alectinib. <i>Journal of Thoracic Oncology</i> , <b>2016</b> , 11, 256-60	8.9	45

150	Sporadic hemangioblastomas are characterized by cryptic VHL inactivation. <i>Acta Neuropathologica Communications</i> , <b>2014</b> , 2, 167	7.3	45
149	Advances in multidisciplinary therapy for meningiomas. <i>Neuro-Oncology</i> , <b>2019</b> , 21, i18-i31	1	44
148	DMD genomic deletions characterize a subset of progressive/higher-grade meningiomas with poor outcome. <i>Acta Neuropathologica</i> , <b>2018</b> , 136, 779-792	14.3	41
147	ENDOCRINE TUMORS: BRAF V600E mutations in papillary craniopharyngioma. <i>European Journal of Endocrinology</i> , <b>2016</b> , 174, R139-44	6.5	41
146	Targeting the PI3K/Akt/mTOR pathway with the pan-Akt inhibitor GDC-0068 in PIK3CA-mutant breast cancer brain metastases. <i>Neuro-Oncology</i> , <b>2019</b> , 21, 1401-1411	1	40
145	L265P mutation and loss are early mutational events in primary central nervous system diffuse large B-cell lymphomas. <i>Blood Advances</i> , <b>2019</b> , 3, 375-383	7.8	40
144	Molecular typing of Meningiomas by Desorption Electrospray Ionization Mass Spectrometry Imaging for Surgical Decision-Making. <i>International Journal of Mass Spectrometry</i> , <b>2015</b> , 377, 690-698	1.9	38
143	Poor prognosis associated with TERT gene alterations in meningioma is independent of the WHO classification: an individual patient data meta-analysis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2020</b> , 91, 378-387	5.5	38
142	Metastatic breast cancers have reduced immune cell recruitment but harbor increased macrophages relative to their matched primary tumors <b>2019</b> , 7, 265		37
141	Clinical and radiographic response following targeting of BCAN-NTRK1 fusion in glioneuronal tumor. <i>Npj Precision Oncology</i> , <b>2017</b> , 1, 5	9.8	37
140	Clinical discussion and review of the management of brain metastases. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2013</b> , 11, 1153-64	7.3	36
139	The Dual PI3K/mTOR Pathway Inhibitor GDC-0084 Achieves Antitumor Activity in -Mutant Breast Cancer Brain Metastases. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 3374-3383	12.9	34
138	Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis. <i>Nature Medicine</i> , <b>2020</b> , 26, 1280-1284	50.5	34
137	Life after surgical resection of a meningioma: a prospective cross-sectional study evaluating health-related quality of life. <i>Neuro-Oncology</i> , <b>2019</b> , 21, i32-i43	1	33
136	Treatment of brain metastases in the modern genomic era. <i>Pharmacology &amp; Therapeutics</i> , <b>2017</b> , 170, 64-72	13.9	32
135	Recent advances in managing brain metastasis. <i>F1000Research</i> , <b>2018</b> , 7,	3.6	32
134	Targeted sequencing of SMO and AKT1 in anterior skull base meningiomas. <i>Journal of Neurosurgery</i> , <b>2017</b> , 127, 438-444	3.2	31
133	Subtype switching in breast cancer brain metastases: a multicenter analysis. <i>Neuro-Oncology</i> , <b>2020</b> , 22, 1173-1181	1	31

132	Genetic Characterization of Brain Metastases in the Era of Targeted Therapy. <i>Frontiers in Oncology</i> , <b>2017</b> , 7, 230	5.3	31
131	Genotype-targeted local therapy of glioma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2018</b> , 115, E8388-E8394	11.5	29
130	Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutations. <i>Cancer</i> , <b>2019</b> , 125, 2910-2914	6.4	28
129	The impact of histopathology and NAB2-STAT6 fusion subtype in classification and grading of meningeal solitary fibrous tumor/hemangiopericytoma. <i>Acta Neuropathologica</i> , <b>2019</b> , 137, 307-319	14.3	28
128	Systemic therapy of brain metastases. <i>Current Neurology and Neuroscience Reports</i> , <b>2015</b> , 15, 518	6.6	27
127	Primary central nervous system lymphoma: overview of current treatment strategies. <i>Hematology/Oncology Clinics of North America</i> , <b>2012</b> , 26, 897-916	3.1	27
126	The Development of Brain Metastases in Patients with Renal Cell Carcinoma: Epidemiologic Trends, Survival, and Clinical Risk Factors Using a Population-based Cohort. <i>European Urology Focus</i> , <b>2019</b> , 5, 474-481	5.1	27
125	Management of Brain Metastases in Patients With Melanoma. <i>Journal of Oncology Practice</i> , <b>2016</b> , 12, 536-42	3.1	25
124	The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients. <i>Neuro-Oncology</i> , <b>2019</b> , 21, 1498-1508	1	25
123	Solitary thoracic osteochondroma: case report and review of the literature. <i>Neurosurgery</i> , <b>2005</b> , 56, E1379; discussion E1379	3.2	25
122	Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , JCO2110231422	10.23	14.22
121	Increased risk of brain metastases in ovarian cancer patients with BRCA mutations. <i>Gynecologic Oncology</i> , <b>2019</b> , 153, 568-573	4.9	21
120	Leptomeningeal disease in melanoma patients: An update to treatment, challenges, and future directions. <i>Pigment Cell and Melanoma Research</i> , <b>2020</b> , 33, 527-541	4.5	21
119	Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors <b>2021</b> , 9,		20
118	A novel intravertebral tumor model in rabbits. <i>Neurosurgery</i> , <b>2005</b> , 57, 341-6; discussion 341-6	3.2	19
117	Aneurysmal bone cysts of the sacrum: a report of ten cases and review of the literature. <i>Iowa orthopaedic journal, The</i> , <b>2009</b> , 29, 74-8	1.1	19
116	Diagnosis and management of craniopharyngiomas in the era of genomics and targeted therapy. <i>Neurosurgical Focus</i> , <b>2016</b> , 41, E2	4.2	19
115	Upfront Surgical Resection of Melanoma Brain Metastases Provides a Bridge Toward Immunotherapy-Mediated Systemic Control. <i>Oncologist</i> , <b>2019</b> , 24, 671-679	5.7	19

114	Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic. <i>Acta Neuropathologica Communications</i> , <b>2020</b> , 8, 171	7.3	18
113	Profiles of brain metastases: Prioritization of therapeutic targets. <i>International Journal of Cancer</i> , <b>2018</b> , 143, 3019-3026	7.5	17
112	Resolving the phylogenetic origin of glioblastoma via multifocal genomic analysis of pre-treatment and treatment-resistant autopsy specimens. <i>Npj Precision Oncology</i> , <b>2017</b> , 1, 33	9.8	17
111	A Clinical Rule for Preoperative Prediction of BRAF Mutation Status in Craniopharyngiomas. <i>Neurosurgery</i> , <b>2019</b> , 85, 204-210	3.2	17
110	Ipilimumab and craniotomy in patients with melanoma and brain metastases: a case series. <i>Neurosurgical Focus</i> , <b>2015</b> , 38, E5	4.2	16
109	Assessment of Effectiveness and Safety of Osimertinib for Patients With Intracranial Metastatic Disease: A Systematic Review and Meta-analysis. <i>JAMA Network Open</i> , <b>2020</b> , 3, e201617	10.4	16
108	Phase II study of pembrolizumab in leptomeningeal carcinomatosis.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 2007-2007	2.2	16
107	Brain Metastasis: Clinical Implications of Branched Evolution. <i>Trends in Cancer</i> , <b>2016</b> , 2, 332-337	12.5	15
106	Anticonvulsant prophylaxis and steroid use in adults with metastatic brain tumors: summary of SNO and ASCO endorsement of the Congress of Neurological Surgeons guidelines. <i>Neuro-Oncology</i> , <b>2019</b> , 21, 424-427	1	14
105	The toxicity of intrathecal bevacizumab in a rabbit model of leptomeningeal carcinomatosis. <i>Journal of Neuro-Oncology</i> , <b>2012</b> , 106, 81-8	4.8	14
104	HIF1A signaling selectively supports proliferation of breast cancer in the brain. <i>Nature Communications</i> , <b>2020</b> , 11, 6311	17.4	13
103	Temozolomide in secondary prevention of HER2-positive breast cancer brain metastases. <i>Future Oncology</i> , <b>2020</b> , 16, 899-909	3.6	13
102	Turner syndrome and meningioma: support for a possible increased risk of neoplasia in Turner syndrome. <i>European Journal of Medical Genetics</i> , <b>2014</b> , 57, 269-74	2.6	13
101	Genomic profiling of brain metastases: current knowledge and new frontiers. <i>Chinese Clinical Oncology</i> , <b>2015</b> , 4, 22	2.3	13
100	Anticonvulsant Prophylaxis and Steroid Use in Adults With Metastatic Brain Tumors: ASCO and SNO Endorsement of the Congress of Neurological Surgeons Guidelines. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 1130-1135	2.2	12
99	A new patient-derived orthotopic malignant meningioma model treated with oncolytic herpes simplex virus. <i>Neuro-Oncology</i> , <b>2016</b> , 18, 1278-87	1	12
98	Emerging Immunotherapies in the Treatment of Brain Metastases. <i>Oncologist</i> , <b>2021</b> , 26, 231-241	5.7	12
97	Evolution of delayed resistance to immunotherapy in a melanoma responder. <i>Nature Medicine</i> , <b>2021</b> , 27, 985-992	50.5	11

96	DeepNeuro: an open-source deep learning toolbox for neuroimaging. <i>Neuroinformatics</i> , <b>2021</b> , 19, 127-140	10.2	11
95	PLEKHA5: A Key to Unlock the Blood-Brain Barrier?. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 1978-80	12.9	10
94	Frequent inactivating mutations of the PBAF complex gene PBRM1 in meningioma with papillary features. <i>Acta Neuropathologica</i> , <b>2020</b> , 140, 89-93	14.3	10
93	Brain metastasis from squamous cell carcinoma of the head and neck: a review of the literature in the genomic era. <i>Neurosurgical Focus</i> , <b>2018</b> , 44, E11	4.2	10
92	Clinical Validation of a Cell-Free DNA Gene Panel. <i>Journal of Molecular Diagnostics</i> , <b>2019</b> , 21, 632-645	5.1	9
91	Vascular endothelial growth factor inhibitors in malignant gliomas. <i>Targeted Oncology</i> , <b>2010</b> , 5, 167-74	5	9
90	Palbociclib demonstrates intracranial activity in progressive brain metastases harboring cyclin-dependent kinase pathway alterations.. <i>Nature Cancer</i> , <b>2021</b> , 2, 498-502	15.4	9
89	Genomic Analysis of Posterior Fossa Meningioma Demonstrates Frequent Mutations in Foramen Magnum Meningiomas. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , <b>2019</b> , 80, 562-567	1.5	8
88	Emerging Gene Fusion Drivers in Primary and Metastatic Central Nervous System Malignancies: A Review of Available Evidence for Systemic Targeted Therapies. <i>Oncologist</i> , <b>2018</b> , 23, 1063-1075	5.7	8
87	Immunotherapy and targeted therapy in brain metastases: emerging options in precision medicine. <i>CNS Oncology</i> , <b>2017</b> , 6, 139-151	4	7
86	Targeting Molecular Pathways in Intracranial Metastatic Disease. <i>Frontiers in Oncology</i> , <b>2019</b> , 9, 99	5.3	7
85	Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis. <i>Nature Communications</i> , <b>2021</b> , 12, 5954	17.4	7
84	VEGF inhibitors in brain tumors. <i>Clinical Advances in Hematology and Oncology</i> , <b>2009</b> , 7, 753-60, 768	0.6	7
83	Modern Management of Central Nervous System Metastases in the Era of Targeted Therapy and Immune Oncology. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2019</b> , 39, e59-e69	7.1	6
82	Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma. <i>JAMA Oncology</i> , <b>2021</b> ,	13.4	6
81	Leptomeningeal Metastases from Solid Tumors: Recent Advances in Diagnosis and Molecular Approaches. <i>Cancers</i> , <b>2021</b> , 13,	6.6	6
80	Immune Checkpoint Inhibitors for Brain Metastases: A Primer for Neurosurgeons. <i>Neurosurgery</i> , <b>2020</b> , 87, E281-E288	3.2	6
79	New molecular targets in meningiomas: the present and the future. <i>Current Opinion in Neurology</i> , <b>2018</b> , 31, 740-746	7.1	6



78	Detection of Leptomeningeal Disease Using Cell-Free DNA From Cerebrospinal Fluid. <i>JAMA Network Open</i> , <b>2021</b> , 4, e2120040	10.4	6
77	Sequencing brain metastases and opportunities for targeted therapies. <i>Pharmacogenomics</i> , <b>2017</b> , 18, 585-594	2.6	5
76	Precision Medical Approaches to the Diagnoses and Management of Brain Metastases. <i>Current Treatment Options in Oncology</i> , <b>2019</b> , 20, 49	5.4	5
75	TERT Alterations in Progressive Treatment-Resistant Meningiomas. <i>Neurosurgery</i> , <b>2018</b> , 65, 66-68	3.2	5
74	A Monoclonal Antibody Against $\alpha$ 5 Integrin Inhibits Proliferation and Increases Survival in an Orthotopic Model of High-Grade Meningioma. <i>Targeted Oncology</i> , <b>2019</b> , 14, 479-489	5	5
73	Central Nervous System-Specific Outcomes of Phase 3 Randomized Clinical Trials in Patients With Advanced Breast Cancer, Lung Cancer, and Melanoma. <i>JAMA Oncology</i> , <b>2021</b> , 7, 1062-1064	13.4	5
72	Enrichment of Amplification in Brain Metastases from Primary Gastrointestinal Malignancies. <i>Oncologist</i> , <b>2019</b> , 24, 193-201	5.7	5
71	Novel approaches in genetic characterization and targeted therapy for brain metastases. <i>Discovery Medicine</i> , <b>2016</b> , 22, 237-250	2.5	5
70	Systemic therapy following craniotomy in patients with a solitary breast cancer brain metastasis. <i>Breast Cancer Research and Treatment</i> , <b>2020</b> , 180, 147-155	4.4	4
69	Toward Precision Medicine in Brain Metastases. <i>Seminars in Neurology</i> , <b>2018</b> , 38, 95-103	3.2	4
68	: meningioma. <i>Neuro-Oncology Practice</i> , <b>2016</b> , 3, 120-134	2.2	4
67	Genomic and transcriptomic correlates of immunotherapy response within the tumor microenvironment of leptomeningeal metastases. <i>Nature Communications</i> , <b>2021</b> , 12, 5955	17.4	4
66	Precision Medicine for Primary Central Nervous System Tumors: Are We There Yet?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2018</b> , 38, 158-167	7.1	4
65	Metastatic breast cancers have reduced immune cell recruitment but harbor increased macrophages relative to their matched primary tumors		3
64	Clinical significance of checkpoint regulator "Programmed death ligand-1 (PD-L1)" expression in meningioma: review of the current status. <i>Journal of Neuro-Oncology</i> , <b>2021</b> , 151, 443-449	4.8	3
63	Genomic characterization of lung tumors and metastatic (Met) sites in advanced (Adv) NSCLC.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 2014-2014	2.2	2
62	Central Nervous System Metastases. <i>Hematology/Oncology Clinics of North America</i> , <b>2022</b> , 36, 161-188	3.1	2
61	TERT promoter mutations in progressive treatment-resistant meningiomas.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 2047-2047	2.2	2

60	Sporadic multiple meningiomas harbor distinct driver mutations. <i>Acta Neuropathologica Communications</i> , <b>2021</b> , 9, 8	7.3	2
59	Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas.. <i>Nature Communications</i> , <b>2022</b> , 13, 1325	17.4	2
58	Brain Metastases from Biliary Tract Cancers: A Case Series and Review of the Literature in the Genomic Era. <i>Oncologist</i> , <b>2020</b> , 25, 447-453	5.7	1
57	NFM-11. PEDIATRIC MENINGIOMAS ARE MOLECULARLY DISTINCT FROM ADULT COUNTERPARTS. <i>Neuro-Oncology</i> , <b>2018</b> , 20, i144-i145	1	1
56	SMO mutant olfactory groove meningiomas-the next in line for targeted therapy. <i>Neuro-Oncology</i> , <b>2017</b> , 19, 305-306	1	1
55	Kairos. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 1562	2.2	1
54	Wiped out. <i>American Journal of Medicine</i> , <b>2009</b> , 122, 1004-6	2.4	1
53	TERT rearrangements to identify a subset of aggressive meningiomas.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, e14028-e14028	2.2	1
52	Leptomeningeal Metastasis <b>2012</b> , 187-200		1
51	Clinically-actionable Mutations in Posterior Skull Base Meningiomas. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , <b>2017</b> , 78, S1-S156	1.5	1
50	62. PRESENCE OF EXTRACRANIAL TUMORS INFLUENCES RESPONSE TO IMMUNE CHECKPOINT INHIBITORS IN A PRE-CLINICAL MODEL OF MELANOMA BRAIN METASTASIS. <i>Neuro-Oncology Advances</i> , <b>2020</b> , 2, ii13-ii13	0.9	1
49	Response to Letter to Editor. <i>Neuro-Oncology</i> , <b>2020</b> , 22, 1706-1707	1	1
48	A rapid genotyping panel for detection of primary central nervous system lymphoma. <i>Blood</i> , <b>2021</b> , 138, 382-386	2.2	1
47	Anti-EGFR VHH-armed death receptor ligand-engineered allogeneic stem cells have therapeutic efficacy in diverse brain metastatic breast cancers. <i>Science Advances</i> , <b>2021</b> , 7,	14.3	1
46	INNV-27. THE IMPACT OF A DEDICATED MULTIDISCIPLINARY TUMOR BOARD ON CARE FOR PATIENTS WITH BRAIN METASTASES. <i>Neuro-Oncology</i> , <b>2019</b> , 21, vi135-vi136	1	1
45	INNV-19. SURVEYING BIAS IN NEURO-ONCOLOGY AND SOCIETY FOR NEURO ONCOLOGY (SNO) MEMBERS: GENDER AND BEYOND. <i>Neuro-Oncology</i> , <b>2019</b> , 21, vi134-vi134	1	1
44	CMET-20. EVIDENCE OF CNS RESPONSE OF PEMBROLIZUMAB FOR LEPTOMENINGEAL CARCINOMATOSIS AT A SINGLE CELL RESOLUTION. <i>Neuro-Oncology</i> , <b>2018</b> , 20, vi57-vi58	1	1
43	Seminoma with Neoplastic Meningitis Treated with Craniospinal Irradiation. <i>Oncologist</i> , <b>2018</b> , 23, 1385-1387	3.8	1

42	CSIG-29. THE DUAL PI3K/mTOR-PATHWAY INHIBITOR GDC-0084 ACHIEVES ANTITUMOR ACTIVITY IN BREAST CANCER BRAIN METASTASES IN VITRO AND IN VIVO. <i>Neuro-Oncology</i> , <b>2018</b> , 20, vi49-vi49	1	1
41	Molecular profiling of pediatric meningiomas shows tumor characteristics distinct from adult meningiomas. <i>Acta Neuropathologica</i> , <b>2021</b> , 142, 873-886	14.3	1
40	Tumor Immune Microenvironment of Brain Metastases: Toward Unlocking Antitumor Immunity.. <i>Cancer Discovery</i> , <b>2022</b> , OF1-OF17	24.4	1
39	DDRE-02. THERAPEUTIC TARGETING OF BRAIN METASTASIS WITH ERK INHIBITOR LY3214996 USING A NOVEL IN VIVO MODEL OF LUNG-TO-BRAIN METASTASIS. <i>Neuro-Oncology</i> , <b>2020</b> , 22, ii61-ii61	1	0
38	IMMU-01. SINGLE CELL SEQUENCING OF MELANOMA BRAIN METASTASES UNVEILS HETEROGENEITY OF THE TUMOR MICROENVIRONMENT IN RESPONSE TO IMMUNE CHECKPOINT BLOCKADE. <i>Neuro-Oncology</i> , <b>2020</b> , 22, ii104-ii104	1	0
37	HER2 positivity in brain metastases from gastrointestinal primary malignancies.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 61-61	2.2	0
36	MYD88 L265P mutation and CDKN2A loss as early mutational events in primary central nervous system lymphomas.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, e14041-e14041	2.2	0
35	Anatomy-oriented stereotactic approach to cerebrospinal fluid collection in mice. <i>Brain Research</i> , <b>2022</b> , 1774, 147706	3.7	0
34	Craniopharyngiomas, including Recurrent Cases, Lack TERT Promoter Hotspot Mutations. <i>Neurologia Medico-Chirurgica</i> , <b>2021</b> , 61, 385-391	2.6	0
33	A broad perspective on evaluating bias in the neuro-oncology workplace. <i>Neuro-Oncology</i> , <b>2021</b> , 23, 498-499	1	0
32	Cross-sectional survey of patients, caregivers, and physicians on diagnosis and treatment of brain metastases. <i>Neuro-Oncology Practice</i> , <b>2021</b> , 8, 662-673	2.2	0
31	Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline. <i>Neuro-Oncology</i> , <b>2022</b> , 24, 331-357	1	0
30	Emerging Systemic Treatment Perspectives on Brain Metastases: Moving Toward a Better Outlook for Patients.. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2022</b> , 42, 1-19	7.1	0
29	Radiation Therapy for Brain Metastases: ASCO Guideline Endorsement of ASTRO Guideline.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , JCO2200333	2.2	0
28	Atypical and Malignant Meningiomas <b>2017</b> , 856-870		
27	TMOD-05. EXTRACRANIAL TUMORS INFLUENCE INTRACRANIAL RESPONSE TO IMMUNE CHECKPOINT INHIBITORS IN PRE-CLINICAL MODELS OF MELANOMA BRAIN METASTASIS. <i>Neuro-Oncology</i> , <b>2020</b> , 22, ii228-ii228	1	
26	NIMG-05. ADVANCED IMAGING TO ASSESS LONGITUDINAL VASCULAR CHANGES IN BRAIN METASTASES TREATED WITH CHECKPOINT INHIBITION. <i>Neuro-Oncology</i> , <b>2020</b> , 22, ii147-ii147	1	
25	PATH-40. INTRAGENIC DMD DELETIONS ARE THE MOST COMMON RECURRENT GENOMIC ALTERATIONS IN ESTHESIONEUROBLASTOMA. <i>Neuro-Oncology</i> , <b>2020</b> , 22, ii173-ii173	1	

24	BIOM-54. A RAPID GENOTYPING PANEL FOR SENSITIVE AND SPECIFIC SEGREGATION OF CNS PATHOLOGIES. <i>Neuro-Oncology</i> , <b>2020</b> , 22, ii13-ii13	1
23	PATH-37. DISTINCT GENOMIC SUBCLASSES OF HIGH-GRADE/PROGRESSIVE MENINGIOMAS: NF2-ASSOCIATED, NF2-EXCLUSIVE, AND NF2-AGNOSTIC. <i>Neuro-Oncology</i> , <b>2021</b> , 23, vi123-vi123	1
22	IMMU-02. GENOMIC AND TRANSCRIPTOMIC CORRELATES OF IMMUNOTHERAPY RESPONSE WITHIN THE TUMOR MICROENVIRONMENT OF LEPTOMENINGEAL METASTASES. <i>Neuro-Oncology</i> , <b>2021</b> , 23, vi92-vi92	1
21	Precision medicine biomarkers in brain metastases: applications, discordances, and obstacles. <i>Neuro-Oncology Advances</i> , <b>2021</b> , 3, v35-v42	0.9
20	Preclinical Solid Tumor Models to Study Novel Therapeutics in Brain Metastases. <i>Current Protocols</i> , <b>2021</b> , 1, e284	
19	CTIM-30. PHASE II TRIAL OF PEMBROLIZUMAB IN RECURRENT AND RESIDUAL HIGH-GRADE MENINGIOMAS. <i>Neuro-Oncology</i> , <b>2021</b> , 23, vi57-vi57	1
18	DDRE-01. CDK PATHWAY INHIBITION WITH ABEMACICLIB IMPROVES INTRACRANIAL AND EXTRACRANIAL RESPONSE TO CHECKPOINT BLOCKADE IN PRE-CLINICAL MODELS OF MELANOMA BRAIN METASTASIS. <i>Neuro-Oncology</i> , <b>2021</b> , 23, vi74-vi74	1
17	QOLP-01. EXPERIENCES FROM PATIENT, CAREGIVER, AND PHYSICIAN SURVEYS ON DIAGNOSIS AND TREATMENT OF BRAIN METASTASES. <i>Neuro-Oncology</i> , <b>2021</b> , 23, vi182-vi182	1
16	BIOM-04. SENSITIVE DETECTION OF LEPTOMENINGEAL DISEASE USING CELL-FREE DNA FROM CEREBROSPINAL FLUID. <i>Neuro-Oncology</i> , <b>2021</b> , 23, vi10-vi10	1
15	CTNI-53. RADIATION TREATMENT VOLUMES BEFORE AND AFTER BRAF/MEK THERAPY IN NEWLY DIAGNOSED PAPILLARY CRANIOPHARYNGIOMAS: A CORRELATIVE ANALYSIS OF THE ALLIANCE A071601 PHASE II TRIAL. <i>Neuro-Oncology</i> , <b>2021</b> , 23, vi72-vi72	1
14	DDRE-03. THERAPEUTIC TARGETING OF THE ERK AND CDK PATHWAYS IN PRECLINICAL MODELS OF BRAIN METASTASES. <i>Neuro-Oncology</i> , <b>2021</b> , 23, vi74-vi75	1
13	CTIM-01. PHASE II TRIAL OF PEMBROLIZUMAB AND LENVATINIB FOR LEPTOMENINGEAL METASTASES. <i>Neuro-Oncology</i> , <b>2021</b> , 23, vi48-vi49	1
12	Clinical characteristics, treatment (Tx) patterns, and overall survival (OS) in advanced (Adv) NSCLC patients (Pts) with and without brain metastases (BM).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 2035-2035 <sup>2.2</sup>	
11	Genomic Characterization of Brain Metastases: Implications for Precision Medicine <b>2020</b> , 43-58	
10	Role of Precision Medicine in Patients with CNS Metastasis <b>2020</b> , 69-82	
9	Emerging Meningioma Therapies II: Immunotherapies, Novel Radiotherapy Techniques, and Other Experimental Approaches <b>2020</b> , 227-238	
8	Contemporary incidence and epidemiologic trends of brain metastases at renal cell carcinoma diagnosis.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 529-529	2.2
7	Neurologic complications of melanoma. <i>Cancer</i> , <b>2020</b> , 126, 477-486	6.4

6	Initial Approach to the Patient with Multiple Newly Diagnosed Brain Metastases. <i>Neurosurgery Clinics of North America</i> , <b>2020</b> , 31, 505-513	4
5	IMMU-08. PHASE II TRIAL OF PEMBROLIZUMAB AND LENVATINIB FOR LEPTOMENINGEAL METASTASES. <i>Neuro-Oncology Advances</i> , <b>2021</b> , 3, iv6-iv6	0.9
4	Biology and pathophysiology of central nervous system metastases <b>2022</b> , 55-78	
3	Abstract P1-21-06: Phase I study of T-DM1 and metronomic temozolomide in secondary prevention of HER2+ breast cancer brain metastases following local radiation therapy. <i>Cancer Research</i> , <b>2022</b> , 82, P1-21-06-P1-21-06	10.1
2	CTIM-02. PHASE II STUDY OF IPILIMUMAB AND NIVOLUMAB IN LEPTOMENINGEAL CARCINOMATOSIS. <i>Neuro-Oncology</i> , <b>2021</b> , 23, vi49-vi49	1
1	PATH-40. SPORADIC NF2 WILD-TYPE MULTIPLE MENINGIOMAS HARBOR DISTINCT DRIVER MUTATIONS. <i>Neuro-Oncology</i> , <b>2021</b> , 23, vi124-vi124	1